Nothing Special   »   [go: up one dir, main page]

SG11202012415PA - Bicyclic peptide ligands specific for nectin-4 - Google Patents

Bicyclic peptide ligands specific for nectin-4

Info

Publication number
SG11202012415PA
SG11202012415PA SG11202012415PA SG11202012415PA SG11202012415PA SG 11202012415P A SG11202012415P A SG 11202012415PA SG 11202012415P A SG11202012415P A SG 11202012415PA SG 11202012415P A SG11202012415P A SG 11202012415PA SG 11202012415P A SG11202012415P A SG 11202012415PA
Authority
SG
Singapore
Prior art keywords
nectin
peptide ligands
ligands specific
bicyclic peptide
bicyclic
Prior art date
Application number
SG11202012415PA
Inventor
Paul Beswick
Liuhong Chen
Gemma Elizabeth Mudd
Peter Park
Rietschoten Katerine Van
Michael Rigby
Original Assignee
Bicycletx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1810250.9A external-priority patent/GB201810250D0/en
Priority claimed from GBGB1815684.4A external-priority patent/GB201815684D0/en
Priority claimed from GBGB1818499.4A external-priority patent/GB201818499D0/en
Priority claimed from GBGB1904632.5A external-priority patent/GB201904632D0/en
Application filed by Bicycletx Ltd filed Critical Bicycletx Ltd
Publication of SG11202012415PA publication Critical patent/SG11202012415PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202012415PA 2018-06-22 2019-06-21 Bicyclic peptide ligands specific for nectin-4 SG11202012415PA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1810250.9A GB201810250D0 (en) 2018-06-22 2018-06-22 Bicycle peptide ligands specific for nectin-4
GBGB1815684.4A GB201815684D0 (en) 2018-09-26 2018-09-26 Bicyclic peptide ligands specific for nectin-4
GBGB1818499.4A GB201818499D0 (en) 2018-11-13 2018-11-13 Bicyclic peptide ligands specific for nectin-4
GBGB1904632.5A GB201904632D0 (en) 2019-04-02 2019-04-02 Bicyclic peptide ligands specific for nectin-4
PCT/GB2019/051741 WO2019243833A1 (en) 2018-06-22 2019-06-21 Bicyclic peptide ligands specific for nectin-4

Publications (1)

Publication Number Publication Date
SG11202012415PA true SG11202012415PA (en) 2021-01-28

Family

ID=67106071

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202012413TA SG11202012413TA (en) 2018-06-22 2019-06-21 Bicyclic peptide ligands specific for nectin-4
SG11202012415PA SG11202012415PA (en) 2018-06-22 2019-06-21 Bicyclic peptide ligands specific for nectin-4

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11202012413TA SG11202012413TA (en) 2018-06-22 2019-06-21 Bicyclic peptide ligands specific for nectin-4

Country Status (14)

Country Link
US (4) US11180531B2 (en)
EP (2) EP3810169A1 (en)
JP (4) JP2021527701A (en)
KR (2) KR20210029783A (en)
CN (2) CN112566651A (en)
AU (2) AU2019289199A1 (en)
BR (2) BR112020025985A2 (en)
CA (2) CA3101164A1 (en)
IL (2) IL279489A (en)
MX (2) MX2021000195A (en)
PH (1) PH12020552179A1 (en)
SG (2) SG11202012413TA (en)
WO (2) WO2019243832A1 (en)
ZA (1) ZA202100442B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032678A (en) 2017-06-26 2020-04-17 拜西克尔德有限公司 Bicyclic peptide ligands with detectable moieties and uses thereof
US11261214B2 (en) 2017-08-04 2022-03-01 Bicycletx Limited Bicyclic peptide ligand specific for CD137
TWI825046B (en) * 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Bicyclic peptide ligands specific for epha2
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
EP3965827A1 (en) 2019-05-09 2022-03-16 BicycleTX Limited Bicyclic peptide ligands specific for ox40
TW202118770A (en) 2019-07-30 2021-05-16 英商拜西可泰克斯有限公司 Heterotandem bicyclic peptide complex
US11508566B2 (en) * 2019-09-03 2022-11-22 National Taiwan University Use of anthranilic acid derivative as matrix for MALDI mass spectrometry
CN114867753A (en) 2019-10-03 2022-08-05 拜斯科技术开发有限公司 Hetero-tandem bicyclic peptide complexes
GB201914872D0 (en) * 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
EP4110369A4 (en) * 2020-02-28 2024-04-03 Ascend Biopharmaceuticals Ltd Methods of treatment and related compositions
JP2023526451A (en) * 2020-05-20 2023-06-21 バイスクルテクス・リミテッド Bicyclic peptide ligands specific for Nectin-4 and uses thereof
CN116234931A (en) 2020-08-17 2023-06-06 拜斯科技术开发有限公司 Bicyclic conjugates with specificity for NECTIN-4 and uses thereof
US20230321062A1 (en) * 2020-09-17 2023-10-12 Mirati Therapeutics, Inc. Combination therapies
GB202016331D0 (en) * 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
JP2024503632A (en) 2021-01-08 2024-01-26 バイスクルテクス・リミテッド Heterotandem bicyclic peptide complex
US20240325554A1 (en) 2021-01-11 2024-10-03 Bicycle TX Limited Methods for treating cancer
AU2022267613A1 (en) * 2021-04-30 2023-11-23 Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. Antibody-drug conjugate targeting nectin-4 and preparation method therefor and use thereof
CN118215672A (en) * 2021-06-01 2024-06-18 南京明德新药研发有限公司 Polypeptide coupling medicine and application thereof
AU2022340959A1 (en) 2021-09-03 2024-03-07 Bicycletx Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
CN118055772A (en) * 2021-09-29 2024-05-17 星联肽(珠海)生物科技有限公司 Tricyclic polypeptide coupling medicine and application thereof
GB202114279D0 (en) * 2021-10-06 2021-11-17 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
WO2023066314A1 (en) * 2021-10-19 2023-04-27 海思科医药集团股份有限公司 Bicyclic peptide ligand for nectin-4 and use thereof
CN114133434B (en) * 2021-12-01 2022-11-15 北京大学第一医院 Nectin-4 targeted bicyclic peptide nuclide ligand and probe
CN116768978A (en) * 2022-03-11 2023-09-19 上海智肽生物科技有限公司 Nectin-4 targeting peptide compounds and drug conjugates thereof
CN115400141B (en) * 2022-09-20 2023-08-11 天津医科大学总医院 Application of STING agonist in preparation of medicine for treating chronic pruritus
WO2024184661A1 (en) 2023-03-09 2024-09-12 Bicycletx Limited Synthesis of bicycle toxin conjugates, and intermediates thereof

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2642514A (en) 1946-08-10 1953-06-16 American Cyanamid Co Ion exchange process with magnetic ion exchange resins
GB1239978A (en) 1968-07-15 1971-07-21 Permutt Company Ltd Ion-exchange processes
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
DK0859841T3 (en) 1995-08-18 2002-09-09 Morphosys Ag Protein / (poly) peptide libraries
GB9819592D0 (en) 1998-09-08 1998-11-04 Smithkline Beecham Plc Novel compounds
US6326144B1 (en) 1998-09-18 2001-12-04 Massachusetts Institute Of Technology Biological applications of quantum dots
US6468808B1 (en) 1998-09-24 2002-10-22 Advanced Research And Technology Institute, Inc. Water-soluble luminescent quantum dots and biomolecular conjugates thereof and related compositions and method of use
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
SI1235830T1 (en) 1999-12-10 2004-06-30 Pfizer Products Inc. PYRROLO(2,3-d)PYRIMIDINE COMPOUNDS AS PROTEIN KINASES INHIBITORS
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
AU2002253619B2 (en) 2001-04-27 2007-05-17 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same active ingredients
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP4488351B2 (en) 2002-02-21 2010-06-23 インスティトゥート オブ ヴァイロロジー Soluble carbonic anhydrase IX (s-CAIX), assay to detect s-CAIX, co-expression of CAIX and HER-2 / neu / c-erbB-2, CAIX specific monoclonal for non-immunodominant epitopes antibody
ATE419865T1 (en) 2002-08-14 2009-01-15 Silence Therapeutics Ag USE OF PROTEIN KINASE-N-BETA
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
MXPA05010471A (en) 2003-04-03 2006-05-25 Semafore Pharmaceuticals Inc Pi-3 kinase inhibitor prodrugs.
ES2382377T3 (en) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Triheterocyclic compounds, compositions, and methods of treating cancer
CA2531069A1 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
EP1720907B1 (en) 2004-02-06 2015-04-08 MorphoSys AG Anti-cd38 human antibodies and uses therefor
US7151047B2 (en) 2004-04-28 2006-12-19 Warren Chan Stable, water-soluble quantum dot, method of preparation and conjugates thereof
LT1761540T (en) 2004-05-13 2017-02-27 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
TWI380996B (en) 2004-09-17 2013-01-01 Hoffmann La Roche Anti-ox40l antibodies
ES2337496T3 (en) 2005-01-19 2010-04-26 Rigel Pharmaceuticals, Inc. PROFESSIONALS OF 2,4-PYRIMIDINDIAMINE COMPOUNDS AND THEIR USES.
EP1844337B1 (en) 2005-01-24 2013-07-03 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
DK1866339T3 (en) 2005-03-25 2013-09-02 Gitr Inc GTR-binding molecules and their applications
TWI337182B (en) 2005-05-12 2011-02-11 Abbott Lab Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1907424B1 (en) 2005-07-01 2015-07-29 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
NZ566837A (en) 2005-10-07 2011-09-30 Exelixis Inc N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as PI3K inhibitors
EP1951684B1 (en) 2005-11-01 2016-07-13 TargeGen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
SI2474545T1 (en) 2005-12-13 2017-03-31 Incyte Holdinges Corporation Heteroaryl substituted pyrrolo(2,3-b)pyridines and pyrrolo(2,3-b)pyrimidines as Janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي PI-3 Kinase inhibitors and methods of their use
CL2007001165A1 (en) 2006-04-26 2008-01-25 Hoffmann La Roche 2- (1h-indazol-4-yl) -6- (4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-yl-thieno [3,2-d] pyrimidine; preparation procedure; pharmaceutical composition; process of preparing said composition; pharmaceutical kit; and use to treat diseases such as cancer, immune disorders and cardiovascular diseases.
MY150757A (en) 2006-09-15 2014-02-28 Siemens Medical Solutions Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
CN104030990B (en) 2007-03-12 2017-01-04 Ym生物科学澳大利亚私人有限公司 Phenyl amino pyrimidine compounds and application thereof
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
AU2008265928A1 (en) 2007-06-18 2008-12-24 Medimmune, Llc Synergistic treatment of cells that express EphA2 and ErbB2
EP3124046B1 (en) 2007-07-12 2019-12-25 GITR, Inc. Combination therapies employing gitr binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CN101932325B (en) 2007-11-30 2014-05-28 新联基因公司 Ido inhibitors
CN102698276B (en) 2008-01-03 2014-12-10 艾克斯-马赛大学 Bitherapy and tritherapy used for treating an HIV-positive patient
DK2474613T3 (en) 2008-02-05 2014-10-06 Bicycle Therapeutics Ltd Methods and compositions
MX2010010012A (en) 2008-03-11 2010-10-20 Incyte Corp Azetidine and cyclobutane derivatives as jak inhibitors.
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
KR20200047793A (en) 2008-12-09 2020-05-07 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
WO2011056652A1 (en) 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
PE20121398A1 (en) 2009-12-10 2012-10-26 Hoffmann La Roche BINDING ANTIBODIES PREFERENTIALLY TO THE EXTRACELLULAR DOMAIN 4 OF HUMAN CSF1R
EP2343081A1 (en) 2009-12-31 2011-07-13 Rijksuniversiteit Groningen Interferon analogs
JP2013518807A (en) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル Multispecific peptide
PT2542256T (en) 2010-03-04 2019-09-05 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CN102918060B (en) 2010-03-05 2016-04-06 霍夫曼-拉罗奇有限公司 Anti-human CSF-1R antibody and uses thereof
RU2617966C2 (en) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Antibodies to human csf-1r and use thereof
NZ712765A (en) 2010-05-04 2017-01-27 Five Prime Therapeutics Inc Antibodies that bind csf1r
HUE041958T2 (en) 2010-09-09 2019-06-28 Pfizer 4-1bb binding molecules
WO2012047724A1 (en) * 2010-09-29 2012-04-12 Agensys, Inc. Antibody drug conjugates (adc) that bind to 191p4d12 proteins
WO2012057624A1 (en) 2010-10-25 2012-05-03 Pepscan Systems B.V. Novel bicyclic peptide mimetics
SI3214091T1 (en) 2010-12-09 2019-02-28 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20130072598A1 (en) 2011-03-18 2013-03-21 Board Of Regents Of The University Of Nebraska Thermoplastics from Distillers Dried Grains and Feathers
NO2694640T3 (en) 2011-04-15 2018-03-17
HUE037651T2 (en) 2011-04-20 2018-09-28 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
SG11201400888TA (en) 2011-10-07 2014-04-28 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
RS61033B1 (en) 2011-11-28 2020-12-31 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
CA2853889A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
CA2861122A1 (en) 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
AR090263A1 (en) 2012-03-08 2014-10-29 Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
RU2670743C9 (en) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR091649A1 (en) 2012-07-02 2015-02-18 Bristol Myers Squibb Co OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
KR20200140400A (en) 2012-08-31 2020-12-15 파이브 프라임 테라퓨틱스, 인크. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
EP3666795A1 (en) 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
US20140274759A1 (en) * 2013-03-15 2014-09-18 Bicycle Therapeutics Limited Modification of polypeptides
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
EP2999483B1 (en) 2013-05-23 2018-10-31 Ohio State Innovation Foundation Chemical synthesis and screening of bicyclic peptide libraries
AU2014343503B2 (en) 2013-10-28 2019-01-17 Bicyclerd Limited Novel polypeptides
US11474101B2 (en) 2014-05-08 2022-10-18 Novodiax, Inc. Direct immunohistochemistry assay
EP3613426A1 (en) 2014-05-21 2020-02-26 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
JP6882978B2 (en) * 2014-10-29 2021-06-02 バイスクルアールディー・リミテッド Bicyclic peptide ligand specific for MT1-MMP
WO2016171242A1 (en) 2015-04-24 2016-10-27 第一三共株式会社 Detection of epha2
KR20170137929A (en) * 2015-04-28 2017-12-13 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) Novel inhibitors of enzyme activator XII (FXIIa)
US10675357B2 (en) * 2015-09-09 2020-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to nectin-4 and uses thereof
EP3429630A1 (en) 2016-03-16 2019-01-23 Merrimack Pharmaceuticals, Inc. Nanoliposomal targeting of ephrin receptor a2 (epha2) and related diagnosticss
MA45328A (en) 2016-04-01 2019-02-06 Avidity Biosciences Llc NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
CA3021618A1 (en) * 2016-04-22 2017-10-26 Alligator Bioscience Ab Novel bispecific polypeptides against cd137
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
US10441663B2 (en) 2016-11-27 2019-10-15 Bicyclerd Limited Methods for treating cancer
KR20230042153A (en) 2016-12-23 2023-03-27 바이사이클티엑스 리미티드 The peptide ligand for the bond about MT1-MMP
EP3559018A1 (en) 2016-12-23 2019-10-30 Bicyclerd Limited Peptide derivatives having novel linkage structures
WO2018127699A1 (en) 2017-01-06 2018-07-12 Bicyclerd Limited Compounds for treating cancer
AU2018224094A1 (en) 2017-02-24 2019-09-19 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
EP3615550A1 (en) 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof
CN111032678A (en) 2017-06-26 2020-04-17 拜西克尔德有限公司 Bicyclic peptide ligands with detectable moieties and uses thereof
US11261214B2 (en) 2017-08-04 2022-03-01 Bicycletx Limited Bicyclic peptide ligand specific for CD137
EP3668550A1 (en) 2017-08-14 2020-06-24 Bicyclerd Limited Bicyclic peptide ligand prr-a conjugates and uses thereof
US20200291096A1 (en) 2017-08-14 2020-09-17 Bicyclerd Limited Bicyclic peptide ligand sting conjugates and uses thereof
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (en) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Bicyclic peptide ligands specific for epha2
US11572370B2 (en) 2018-01-08 2023-02-07 Biohaven Therapeutics Ltd. CD16A binding agents and uses thereof
US10875894B2 (en) 2018-02-23 2020-12-29 Bicycletx Limited Multimeric bicyclic peptide ligands
AU2019247795B2 (en) 2018-04-04 2024-08-15 Bicycletx Limited Heterotandem bicyclic peptide complexes
CA3099308A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US10919937B2 (en) 2018-10-23 2021-02-16 Bicycletx Limited Bicyclic peptide ligands and uses thereof
US20200129630A1 (en) 2018-10-30 2020-04-30 Bicyclerd Limited Methods for treating cancer
KR20210123295A (en) 2018-12-13 2021-10-13 바이사이클티엑스 리미티드 Bicyclic peptide ligand specific for MT1-MMP
JP2022514262A (en) 2018-12-17 2022-02-10 レビトープ リミテッド Twin Immune Cell Engager
CN113474045A (en) 2018-12-21 2021-10-01 拜斯科技术开发有限公司 PD-L1 specific bicyclic peptide ligands
US10882987B2 (en) 2019-01-09 2021-01-05 Nova Chemicals (International) S.A. Ethylene interpolymer products having intermediate branching
WO2020178574A1 (en) 2019-03-04 2020-09-10 Bicyclerd Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
WO2020201753A1 (en) 2019-04-02 2020-10-08 Bicycletx Limited Bicycle toxin conjugates and uses thereof
EP3965827A1 (en) 2019-05-09 2022-03-16 BicycleTX Limited Bicyclic peptide ligands specific for ox40
TW202108165A (en) 2019-05-10 2021-03-01 英商拜西克爾德有限公司 Methods for treating cancer
TW202118770A (en) 2019-07-30 2021-05-16 英商拜西可泰克斯有限公司 Heterotandem bicyclic peptide complex
WO2021028686A1 (en) 2019-08-13 2021-02-18 Bicycletx Limited Modified multimeric bicyclic peptide ligands
CN114867753A (en) 2019-10-03 2022-08-05 拜斯科技术开发有限公司 Hetero-tandem bicyclic peptide complexes
GB201914872D0 (en) 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
WO2021074647A1 (en) 2019-10-16 2021-04-22 Bicyclerd Limited Methods for treating cancer
CA3158741A1 (en) 2019-11-27 2021-06-03 Gavin Bennett Bicyclic peptide ligands specific for epha2 and uses thereof
JP2023526451A (en) 2020-05-20 2023-06-21 バイスクルテクス・リミテッド Bicyclic peptide ligands specific for Nectin-4 and uses thereof
US20230233698A1 (en) 2020-06-12 2023-07-27 Bicycletx Limited Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)
CN116234931A (en) 2020-08-17 2023-06-06 拜斯科技术开发有限公司 Bicyclic conjugates with specificity for NECTIN-4 and uses thereof
JP2024503632A (en) 2021-01-08 2024-01-26 バイスクルテクス・リミテッド Heterotandem bicyclic peptide complex
US20240325554A1 (en) 2021-01-11 2024-10-03 Bicycle TX Limited Methods for treating cancer
AU2022340959A1 (en) 2021-09-03 2024-03-07 Bicycletx Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
EP4433025A1 (en) 2021-11-16 2024-09-25 BicycleTx Limited Methods for treating cancer

Also Published As

Publication number Publication date
JP2021527702A (en) 2021-10-14
CA3101427A1 (en) 2019-12-26
US11180531B2 (en) 2021-11-23
CN112601539A (en) 2021-04-02
US11912792B2 (en) 2024-02-27
KR20210025603A (en) 2021-03-09
MX2020013784A (en) 2021-03-02
WO2019243833A1 (en) 2019-12-26
AU2019289200A1 (en) 2021-02-11
CA3101164A1 (en) 2019-12-26
BR112020025985A2 (en) 2021-03-23
US20210269480A1 (en) 2021-09-02
TW202016129A (en) 2020-05-01
US20190389906A1 (en) 2019-12-26
IL279489A (en) 2021-01-31
EP3810167A1 (en) 2021-04-28
MX2021000195A (en) 2021-03-25
BR112020025715A2 (en) 2021-04-06
SG11202012413TA (en) 2021-01-28
ZA202100442B (en) 2022-08-31
WO2019243832A1 (en) 2019-12-26
US20230287047A1 (en) 2023-09-14
US20220089643A1 (en) 2022-03-24
JP2024062999A (en) 2024-05-10
US11453702B2 (en) 2022-09-27
CN112566651A (en) 2021-03-26
JP2024122976A (en) 2024-09-10
AU2019289199A1 (en) 2021-02-11
JP2021527701A (en) 2021-10-14
PH12020552179A1 (en) 2021-06-28
EP3810169A1 (en) 2021-04-28
IL279488A (en) 2021-01-31
KR20210029783A (en) 2021-03-16

Similar Documents

Publication Publication Date Title
ZA202100442B (en) Bicyclic peptide ligands specific for nectin-4
IL275437A (en) Bicyclic peptide ligands specific for epha2
GB201721265D0 (en) Bicyclic peptide ligands specific for EphA2
IL283873A (en) Bicyclic peptide ligands specific for mt1-mmp
GB201820316D0 (en) Bicyclic peptide ligands specific for IL-17
IL283874A (en) Bicyclic peptide ligands specific for mt1-mmp
GB201820325D0 (en) Bicyclic peptide ligands specific for psma
GB201820295D0 (en) Bicyclic peptide ligands specific for MT1-MMP
GB201820320D0 (en) Bicyclic peptide ligands specific for FAPalpha
GB201818499D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201815684D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201918495D0 (en) Bicyclic peptide ligands specific for il-46
GB201904632D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201720934D0 (en) Bicyclic peptide ligands specific for FAPalpha
GB201820956D0 (en) Bicyclic peptide ligands specific for pd-l1
GB201818603D0 (en) Bicyclic peptide ligands specific for epha2
GB201820312D0 (en) Bicyclic peptide ligands specific for IL-6
GB201712693D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201820314D0 (en) Bicyclic peptide ligands specific for KLK7
GB201820324D0 (en) Bicyclic peptide ligands specific for vegf
GB201820318D0 (en) Bicyclic peptide ligands specific for cathepsin G
GB201820326D0 (en) Bicyclic peptide ligands specific for epha3
GB201820313D0 (en) Bicyclic peptide ligands specific for KLK5
GB201820321D0 (en) Bicyclic peptide ligands specific for MMP9
GB201820310D0 (en) Bicyclic peptide ligands specific for Hsp90